CRSP vs. JD

In the year-to-date period, CRSP achieves a -24.52% return, which is significantly lower than JD's 25.09% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and JD.com, Inc. (JD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current CRSP Sharpe Ratio is -0.30, which is lower than the JD Sharpe Ratio of 0.54. The chart below compares the historical Sharpe Ratios of CRSP and JD, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

CRSP has not paid dividends to shareholders, while JD's dividend yield for the trailing twelve months is around 2.10%.

The maximum CRSP drawdown since its inception was -81.61%, roughly equal to the maximum JD drawdown of -79.14%. Use the drawdown chart below to compare losses from any high point for CRSP and JD. For additional features, visit the drawdowns tool.

CRISPR Therapeutics AG (CRSP) has a higher volatility of 17.94% compared to JD.com, Inc. (JD) at 16.92%. This indicates that CRSP's price experiences larger fluctuations and is considered to be riskier than JD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between CRISPR Therapeutics AG and JD.com, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.